Janssen Biotech, Inc. drugs
11 results
Darzalex (daratumumab)
(Daratumumab)Janssen Biotech, Inc.
Usage: DARZALEX is indicated for treating adult patients with multiple myeloma, including those newly diagnosed or with relapsed/refractory disease. It can be used in combination with various therapies or as monotherapy in patients who have undergone multiple prior treatments.
Darzalex faspro (daratumumab and hyaluronidase-fihj (human recombinant))
(daratumumab and hyaluronidase-fihj (human recombinant))Janssen Biotech, Inc.
Usage: DARZALEX FASPRO is indicated for treating adult patients with multiple myeloma and newly diagnosed light chain (AL) amyloidosis. It may be used in various combinations with other therapies and is not recommended for patients with severe cardiac conditions related to AL amyloidosis.
Remicade (infliximab)
(INFLIXIMAB)Janssen Biotech, Inc.
Usage: REMICADE is indicated for treating moderately to severely active Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults and pediatric patients (6+ years). It helps reduce symptoms, maintain remission, and improve physical function for patients unresponsive to conventional therapies.
Rybrevant (amivantamab)
(Amivantamab)Janssen Biotech, Inc.
Usage: RYBREVANT is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) with specific EGFR mutations. It can be used as a first-line treatment in combination with lazertinib or carboplatin and pemetrexed, or as a single agent for previously treated patients with EGFR exon 20 mutations.
Simponi (golimumab)
(golimumab)Janssen Biotech, Inc.
Usage: SIMPONI is indicated for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderately to severely active ulcerative colitis in adults. It can be used alone or in combination with methotrexate, depending on the condition.
Simponi aria (golimumab)
(golimumab)Janssen Biotech, Inc.
Usage: SIMPONI ARIA is indicated for treating moderately to severely active rheumatoid arthritis in adults, active psoriatic arthritis in patients aged 2 and older, active ankylosing spondylitis in adults, and active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.
Stelara (ustekinumab)
(ustekinumab)Janssen Biotech, Inc.
Usage: STELARA® is indicated for treating moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in those 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.
Tecvayli (teclistamab)
(teclistamab)Janssen Biotech, Inc.
Usage: TECVAYLI is indicated for treating adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Continued approval may depend on confirmatory trials.
Tremfya (guselkumab)
(Guselkumab)Janssen Biotech, Inc.
Usage: TREMFYA is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis and Crohn's disease. It is suitable for patients who are candidates for systemic therapy or phototherapy.
Ustekinumab (ustekinumab)
(ustekinumab)Janssen Biotech, Inc.
Usage: Ustekinumab is indicated for treating moderate to severe plaque psoriasis in adults and children (≥6 years), active psoriatic arthritis in adults and children (≥6 years), and moderately to severely active Crohn's disease and ulcerative colitis in adults.